OxyContin's new formulation approved by FDA
A reformulation of controlled-release oxycodone (OxyContin, Purdue Pharma), designed to curb misuse and abuse of the drug, has received FDA approval.
A reformulation of controlled-release oxycodone (OxyContin, Purdue Pharma), designed to curb misuse and abuse of the drug, has received FDA approval.
The new composition of the drug is designed to keep the opioid from being broken, chewed, crushed, cut, or dissolved to deliver more medication. The modified drug composition may lead to less risk of overdose related to tampering and may lead to less abuse through injection or inhalation of the substance. However, it can still be misused through use of the drug in greater doses.
The drug’s manufacturer is mandated to establish a post-market study to gather data on whether the new formulation reduces abuse and misuse of this opioid. The FDA also requires a REMS necessitating that providers give a Medication Guide to patients and that providers receive information about the proper use of opioid analgesics for treatment of pain.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.
